雷帕鸣哪里有售？

(sirolimus) belongs to the macrolides, which has strong anti-rejection effect and the ability to prolong graft survival. Its mechanism of action is different from calcineurin inhibitors (CNI) and new immunosuppressants of antimetabolite drugs. The advantage of rapamin lies in its highly effective immunosuppressive effect, no CNI nephrotoxicity, and anti-proliferative and anti-tumor effects.

In 1999, Rapamin was approved by the U.S. FDA and officially launched in the United States. It was not until 2002 that the drug was finally approved for domestic marketing, providing certain help in the treatment of many domestic kidney transplant patients. From that time on, patients can purchase the medicines they need at major hospitals and pharmacies in the country. Another good news is that Leipamin has been included in the national medical insurance catalog and is a Class B drug. When patients purchase drugs, they can rely on medical insurance to reimburse part of the cost, thus achieving the purpose of reducing out-of-pocket expenses.

However, despite this, many patients are still unable to afford the drugs after medical insurance, so many domestic patients choose to purchase more cost-effective drugs overseas, including India's Biocon's Rapamin. Since this version of the drug is currently only available overseas, patients in need can only purchase the drug overseas first. Since the exchange rate floating price is not fixed, if patients want to know the specific price of sirolimus or want to purchase the drug overseas, they can consult with domestic reliable overseas medical service institutions (such as Medical Companion Travel).

On November 29, 1978, India's Biocon was registered as Biocon Biochemical Co., Ltd., a joint venture, and has since provided cheaper drugs for the treatment of many patients around the world. Among them, India's Biocon has also been welcomed and favored by many patients once it was launched.

Recommended hot articles: /newsDetail/92431.html